Deciphera Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven L. Hoerter
- Full Time Employees
- 355
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 200 Smith Street Waltham MA United States of America 02451
- IPO Date
- Sep 28, 2017
- CIK
- 0001654151
- Website
- deciphera.com
- Similar Companies
- Business
- Deciphera Pharmaceuticals, Inc. (DCPH) develops and commercializes kinase inhibitor therapies targeting tumor and drug resistance mechanisms to improve outcomes for cancer patients; the company leverages its proprietary switch-control kinase inhibitor platform and expertise in kinase biology to create highly selective oral drugs for oncology indications including gastrointestinal stromal tumors (GIST), tenosynovial giant cell tumor (TGCT), and other solid tumors. Core products include QINLOCK (ripretinib), a marketed fourth-line therapy for advanced GIST approved in the U.S., Europe, and other regions; and ROMVIMZA (vimseltinib), approved by the European Commission for TGCT and supported by 2-year Phase 3 MOTION study data presented in 2025 showing sustained efficacy and safety. The pipeline encompasses late-stage and preclinical candidates such as DCC-3116, DCC-3084, DCC-3009, tirabrutinib, sapablursen, ONO-4578, ONO-2808, ONO-2020, inlexisertib, and DCC-2812, targeting oncology, immunology, neurology, and specialty areas with first-in-class mechanisms. Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera operates globally with key facilities in the U.S., a European headquarters in Zug, Switzerland established in 2021 and expanded with a new 733-square-meter office, and additional sites in Lawrence, Kansas; Paris, France; Milan, Italy; Munich, Germany; and Barcelona, Spain. The company serves patients and healthcare providers worldwide, focusing on commercial-stage biopharmaceutical delivery through its U.S. and European sales infrastructure. In June 2024, ONO Pharmaceutical Co., Ltd. completed its $2.4 billion acquisition of Deciphera for $25.60 per share, integrating it as a wholly-owned subsidiary to bolster ONO's oncology portfolio, global R&D, and sales platforms in the U.S. and Europe; Deciphera was delisted from Nasdaq following the merger. As part of post-merger integration, ONO consolidated its U.S. and European development and sales bases into Deciphera in July 2025, accelerating globalization and pipeline expansion with synergies in switch-control technology and first-in-class candidates like QINLOCK and ROMVIMZA. Recent advancements include multiple 2025 data presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting and European Society for Medical Oncology (ESMO) Congress on ROMVIMZA's long-term results.
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
Deciphera Announces the Opening of a New Office in Zug, Switzerland
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH
ONO to buy Deciphera Pharmaceuticals at a huge premium
ONO to buy Deciphera Pharmaceuticals at a huge premium
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion